bioAffinity Technologies, Inc. (BIAF)

NASDAQ: BIAF · Real-Time Price · USD
0.5100
+0.0404 (8.60%)
At close: Apr 17, 2025, 4:00 PM
0.5000
-0.0100 (-1.96%)
After-hours: Apr 17, 2025, 5:17 PM EDT
8.60%
Market Cap 9.22M
Revenue (ttm) 9.36M
Net Income (ttm) -9.04M
Shares Out 17.91M
EPS (ttm) -0.75
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 472,656
Open 0.5000
Previous Close 0.4696
Day's Range 0.4950 - 0.5800
52-Week Range 0.2400 - 3.1630
Beta 3.47
Analysts Hold
Price Target n/a
Earnings Date May 14, 2025

About BIAF

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung. It offers CyPath lung, a diagnostic test, for early detection of lung cancer. The company was incorporated in 2014 and is based in San Antonio, Texas. [Read more]

Sector Healthcare
IPO Date Sep 1, 2022
Employees 57
Stock Exchange NASDAQ
Ticker Symbol BIAF
Full Company Profile

Financial Performance

In 2024, bioAffinity Technologies's revenue was $9.36 million, an increase of 269.68% compared to the previous year's $2.53 million. Losses were -$9.04 million, 13.9% more than in 2023.

Financial Statements

News

bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies is implementing efficiency measures for CyPath Lung that streamline lab processing and data acquisition and reduce lab costs.

1 day ago - Business Wire

bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies, Inc. (BIAF) releases financial results for 2024.

18 days ago - Business Wire

Case Study: bioAffinity Technologies' CyPath® Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies' CyPath Lung test uncovered a hidden second primary lung cancer in a patient who had been treated for lung cancer earlier.

23 days ago - Business Wire

Case Study: bioAffinity Technologies' Positive CyPath® Lung Result Leads to Detecting Breast Cancer Recurrence

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--In another case study, CyPath® Lung helped physicians identify and treat a recurrence of breast cancer in a high-risk patient.

4 weeks ago - Business Wire

Physicians' Case Studies Offer Insight into Use and Benefit of CyPath® Lung in Avoiding Unnecessary Invasive Procedures and Detecting Lung Cancer

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--Case studies highlight the benefit of CyPath Lung to both physicians and patients, including avoiding unnecessary invasive procedures.

5 weeks ago - Business Wire

bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath® Lung Sales Growth

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies today announced strategic actions to cut $4 million in annual costs at its subsidiary CAP/CLIA pathology laboratory.

6 weeks ago - Business Wire

WallachBeth Capital Announces Closing of bioAffinity Technologies Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million

JERSEY CITY, N.J. , Feb. 26, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that – bioAffinity Technologies, ...

7 weeks ago - PRNewsWire

bioAffinity Technologies Announces Closing of Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces closing of warrant inducement transaction for aggregate gross proceeds of $1.4 million.

7 weeks ago - Business Wire

WallachBeth Capital Announces bioAffinity Technologies Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million

JERSEY CITY, N.J. , Feb. 25, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, In...

7 weeks ago - PRNewsWire

bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity has entered into warrant exercise agreements to exercise certain outstanding warrants for gross cash proceeds of $1.4 million.

7 weeks ago - Business Wire

bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--The Australian patent office accepted bioAffinity Technologies' patent application on the method CyPath Lung uses to detect early-stage lung cancer.

3 months ago - Business Wire

bioAffinity Technologies Reports Positive Results from Texas Beta Launch of CyPath® Lung

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports positive results of the 2024 beta test market launch of CyPath Lung in Texas.

3 months ago - Business Wire

Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESSWIRE / January 10, 2025 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (Nasdaq:ENLV) and bioAffinity Technologies, Inc. (Nasdaq:BIAF) on the RedChip Small S...

Other symbols: ENLV
3 months ago - Accesswire

Join bioAffinity Technologies' Exclusive Live Investor Webinar and Q&A Session on Thursday, December 19

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies President and CEO Maria Zannes will be featured on RedChip Companies' investor webinar on Thursday, Dec. 19.

4 months ago - Business Wire

bioAffinity Technologies Set for Continued Expansion in 2025

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity reports successful execution of its pilot marketing program and steady growth in sales of the CyPath® Lung test in 2024.

4 months ago - Business Wire

bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies releases financial results for the three months ended September 30, 2024.

5 months ago - Business Wire

bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies promotes Senior VP William Bauta, Ph.D., to Chief Science Officer to spearhead product development.

5 months ago - Business Wire

bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies receives a Japanese patent for the method behind the CyPath® Lung diagnostic test for early-stage lung cancer.

6 months ago - Business Wire

WallachBeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private Placement

JERSEY CITY, N.J. , Oct. 21, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, In...

6 months ago - PRNewsWire

bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces closing of $2.6 million registered direct offering and concurrent private placement.

6 months ago - Business Wire

WallachBeth Capital Announces Pricing of bioAffinity Technologies $2.66 Million Registered Direct Offering & Concurrent Private Placement

JERSEY CITY, N.J. , Oct. 18, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that– bioAffinity Technologies, I...

6 months ago - PRNewsWire

bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces pricing of $2.66 million registered direct offering and concurrent private placement.

6 months ago - Business Wire

bioAffinity's CyPath® Lung Cancer Test Supported by Newly Published Flow Cytometry Guidelines

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity VP served on expert panel to update flow cytometry guidelines for unique biological samples like sputum used in CyPath® Lung.

6 months ago - Business Wire

bioAffinity Technologies Names J. Michael Edwards as Chief Financial Officer

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies names J. Michael Edwards as Chief Financial Officer.

6 months ago - Business Wire

bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies' CyPath® Lung test will be added to the Federal Supply Schedule to help veterans and active military at risk for lung cancer.

6 months ago - Business Wire